Bureaucrats, editor, reviewer, Administrators
6,387
edits
ADRENAL: Difference between revisions
Jump to navigation
Jump to search
→Design
m (→Major Points: format update) |
(→Design) |
||
| Line 43: | Line 43: | ||
==Design== | ==Design== | ||
* | * Multicenter, double-blind, parallel-group, randomized, controlled trial | ||
* N= | * N=3658 | ||
** Hydrocortisone (n=1832) | ** Hydrocortisone (n=1832) | ||
** Placebo (n=1826) | ** Placebo (n=1826) | ||
* Setting: Australia (45 sites), UK (12), New Zealand (8), Saudi Arabia (3), and Denmark (1) | * Setting: Australia (45 sites), UK (12), New Zealand (8), Saudi Arabia (3), and Denmark (1) | ||
* Enrollment: | * Enrollment: 2013-2017 | ||
* | * Follow-up: 90 days | ||
* Analysis: Intention-to-treat | * Analysis: Intention-to-treat | ||
* Primary Outcome: 90 day mortality | * Primary Outcome: 90 day mortality | ||